Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BiondVax Pharmaceuticals (BVXV)

BiondVax Pharmaceuticals Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BVXV
DateTimeSourceHeadlineSymbolCompany
30/04/202421:06Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
16/04/202422:27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
10/04/202412:00PR Newswire (US)Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202420:17Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202412:00PR Newswire (US)Scinai leadership to attend BIO-Europe Spring 2024NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
13/02/202412:00PR Newswire (US)Scinai Welcomes Liat Halpert as Head of Business Development and SalesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
04/01/202421:01PR Newswire (US)Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
20/11/202312:30PR Newswire (US)Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity RuleNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/09/202322:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/09/202317:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/09/202316:44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/09/202311:00GlobeNewswire Inc.BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological TherapeuticsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
28/08/202321:01Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
28/08/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
24/08/202321:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/08/202311:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202321:16Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202315:07Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
14/08/202311:08Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/08/202314:44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/08/202314:00GlobeNewswire Inc.BiondVax Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
01/08/202321:01GlobeNewswire Inc.Nasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
01/08/202321:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/07/202320:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/07/202313:17GlobeNewswire Inc.IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
05/07/202314:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/07/202321:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/07/202321:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/06/202321:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
05/06/202312:00GlobeNewswire Inc.BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:BVXV